References
- MacDonald TT, Hutchings P, Choy MV, Murch S, Cooke A. Tumour necrosis factor-alpha and interferon-gamma production measured at the single cell level in normal and inflamed human intestine. Clin Exp Immunol 1990;81:301–5.
- Schreiber S, Nikolaus S, Hampe J, Hamling J, Koop I, Groessner B, et al. Tumor necrosis factor α and interleukin 1β in relapse of Crohn’s disease. Lancet 1999;353:459–61.
- Reinecker HC, Steffen M, Witthoeft T, Pflueger I, Schreiber I, MacDermott RP, et al. Enhanced secretion of tumour necrosis factor alpha, IL-6, and IL-1β by isolated lamina propria mononuclear cells from patients with ulcerative colitis and Crohn’s disease. Clin Exp Immunol 1993;94:174–81.
- Prehn JL, Landers CJ, Targan SR. A soluble factor produced by lamina propria mononuclear cells is required for TNF-alpha enhancement of IFN-gamma production by T cells. J Immunol 999;163: 4277–83.
- Agnholt J, Kaltoft K. Infliximab a chimeric TNF-alpha antibody downregulates IFN-gamma production in gut derived T lymphocytes from patients with Crohn’s disease. Cytokine 2001;15:212–22.
- van Deventer SJ. Tumor necrosis factor and Crohn’s disease. Gut 1997;40:443–8.
- Breese EJ, Michie CA, Nicholls SW, Murch SH, Williams CB, Domizio P, et al. Tumor necrosis factor α-producing cells in the intestinal mucosa of children with inflammatory bowel disease. Gastroenterology 1994;106:1455—66.
- Scheinin T, Bohling T, Halme L, Kontiainen S, Bjorge L, Meri S. Decreased expression of protectin (CD59) in gut epithelium in ulcerative colitis and Crohn’s disease. Hum Pathol 1999; 30: 1427—30.
- Cavaillon JM, Fitting C, Haeffner—Cavaillon N. Recombinant C5a enhances interleukin 1 and tumor necrosis factor release by lipopolysaccharide-stimulated monocytes and macrophages. Eur J Immunol 1990;20: 253–7.
- Walport MJ. Review articles: Advances in immunology: Complement. N Engl J Med 2001;344:1058–66 and 1140–4.
- Targan S, Hanauer SB, van Deventer SJH, Mayer L, Present DH, Braakman T, et al. A short-term study of chimeric monoclonal antibody cA2 to tumour necrosis factor alpha for Crohn’s disease. N Engl J Mede 1997;337:1029–35.
- D’Haens G, van Deventer S, van Hogezand R, Chalmers D, Kothe C, Baert D, et al. Endoscopic and histological healing with infliximab anti tumour necrosis factor antibodies in Crohn’s disease: A European multicenter trial. Gastroenterology 1999; 116:1029–34.
- Baert FJ, D’Haens G, Peeters M, Hiele MI, Schaible TF, Shealy D, et al. Tumor necrosis factor alpha antibody (infliximab) therapy profoundly down-regulates the inflammation in Crohn’s ileocolitis. Gastroenterology 1999;116:22–8.
- Scallon BJ, Moore MA, Trinh H, Knight DM, Ghrayeb J. Chimeric anti-TNF-α monoclonal antibody cA2 binds recombinant transmembrane TNF-α and activates immune effector functions. Cytokine 1995;7: 251–9.
- Hanauer SB, Feagan BG, Lichtenstein GR, Mayer LF, Schreiber S, Colombel JF, et al, and the ACCENT I study group. Maintenance Infliximab for Crohn’s disease: the ACCENT I randomised trial. Lancet 2002;359:1541–9.
- Best WR, Becktel JM, Singleton JW, Kern F Jr. Development of a Crohn’s disease activity index. National Cooperative Crohn’s disease Study. Gastroenterology 1976;70:439–44.
- Mary JY, Modigliani R, (for the Groupe d’Etudes Thera- peutiques des Affectiones Inflammatoires du Tube Digestif (GETAID). Development and validation of an endoscopic index of the severity for Crohn’s disease: a prospective multicenter study. Gut 1989;30:983–9.
- Zimmermann-Nielsen E, Svehag S-E, Thorlacius-Ussing O, Baatrup G. ELISA for incorporation of plasma derived complement split-products C3b/iC3b into solid-phase immune complexes. J Immunol Meth 2001;249: 43–51.
- Super M, Thiel S, Lu J, Turner MW. Association of low levels of mannan-binding protein with a common defect in opsonization. Lancet 1989;ii:1236–9.
- Zimmermann-Nielsen E, Baatrup G, Thorlacius-Ussing O, Agnholt J, Svehag S-E. Complement activation mediated by mannan-binding lectin in plasma from healthy individuals and patients with SLE, Crohn’s disease and colorectal cancer. Suppressed activation by SLE plasma. Scand J Immunol 2002; 55:105–10.
- Ten Hove T, van Montfrans C, Peppelenbosch MP, van Deventer SJ. Infliximab treatment induces apoptosis of lamina propria T lymphocytes in Crohn’s disease. Gut 2002;50:206–11.
- Halstensen TS, Mollnes TE, Garred P, Fausa O, Brandtzaeg P. Surface epithelium related activation of complement differs in Crohn’s disease and ulcerative colitis. Gut 1992;33:902–8.